|Day Low/High||9.28 / 9.54|
|52 Wk Low/High||5.23 / 19.75|
Six of the eight active names are in positive territory.
Since the last update, both portfolios are up about 9%, keeping the performance gap at about 1700 bps.
While this experiment is still inconclusive, it's still nice to see both groups of triple nets outperforming.
The two portfolios, one active and the other passive, have sagged with the broader market but still are outperforming a pair of Russell value indices.
One thing is certain: Triple-nets are not a common investment hunting ground, but some may be the recipe for the next ETF.
The portfolio has outperformed the Russell 2000 index by more than 400 basis points, year to date.
Shares of the pharmaceutical company were climbing Wednesday on news of a $16.6 million contract awarded.
Shares of Express were tanking in premarket trading after the apparel retailer posted worse-than-expected earnings.
We're looking to add to our positions in companies we believe can outperform in coming quarters
Akers Biosciences makes rapid, point-of-care screening and testing products designed to rapidly bring health care information direct to the consumer or provider.
These high-potential names are down for the year but could pay off big.
Doug Michels, CEO of OraSure, explains why he's so excited about his company's OraQuick in-home HIV test.